Sanofi Aventis Us Drug Patent Portfolio
Sanofi Aventis Us owns 16 orange book drugs protected by 88 US patents with Ambien Cr having the least patent protection, holding only 2 patents. And Apidra Solostar with maximum patent protection, holding 23 patents. Given below is the list of Sanofi Aventis Us's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9186346 | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients | 04 Aug, 2034 | Active |
| US9186346 | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients | 04 Feb, 2034 | Active |
| US9717852 | Cartridge holder and pen-type injector | 08 Apr, 2033 | Active |
| US8602215 | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation | 30 Jun, 2031 | Active |
| US8927592 | Antitumoral use of cabazitaxel | 27 Apr, 2031 | Active |
| US8802735 | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability | 14 Mar, 2031 | Active |
| US10583110 | Antitumoral use of cabazitaxel | 27 Oct, 2030 | Active |
| US10716777 | Antitumoral use of cabazitaxel | 27 Oct, 2030 | Active |
| US8927592 | Antitumoral use of cabazitaxel | 27 Oct, 2030 | Active |
| US8802735 | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability | 14 Sep, 2030 | Active |
| US8410167 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality | 16 Apr, 2029 | Active |
| US9107900 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality | 16 Apr, 2029 | Active |
| US7918833 | Pen-type injector | 23 Mar, 2028 | Active |
| US7918833 | Pen-type injector | 23 Sep, 2027 | Active |
| US6794410 | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis | 12 Mar, 2027 | Active |
| US6794410 | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis | 12 Sep, 2026 | Active |
| US7241907 | Acetone solvate of dimethoxy docetaxel and its process of preparation | 10 Jun, 2026 | Active |
| US7241907 | Acetone solvate of dimethoxy docetaxel and its process of preparation | 10 Dec, 2025 | Active |
| US8679069 | Pen-type injector | 12 Apr, 2025 | Active |
| US8512297 | Pen-type injector | 15 Sep, 2024 | Expired |
| US9561331 | Drive mechanisms suitable for use in drug delivery devices | 28 Aug, 2024 | Expired |
| US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices | 19 Aug, 2024 | Expired |
| US9533105 | Drive mechanisms suitable for use in drug delivery devices | 17 Aug, 2024 | Expired |
| US9604009 | Drive mechanisms suitable for use in drug delivery devices | 16 Aug, 2024 | Expired |
| US8992486 | Pen-type injector | 05 Jun, 2024 | Expired |
| US9011391 | Pen-type injector | 26 Mar, 2024 | Expired |
| US8556864 | Drive mechanisms suitable for use in drug delivery devices | 03 Mar, 2024 | Expired |
| US8603044 | Pen-type injector | 02 Mar, 2024 | Expired |
| US9233211 | Relating to a pen-type injector | 02 Mar, 2024 | Expired |
| US9408979 | Pen-type injector | 02 Mar, 2024 | Expired |
| US9526844 | Pen-type injector | 02 Mar, 2024 | Expired |
| US9604008 | Drive mechanisms suitable for use in drug delivery devices | 02 Mar, 2024 | Expired |
| US9610409 | Drive mechanisms suitable for use in drug delivery devices | 02 Mar, 2024 | Expired |
| US9775954 | Pen-type injector | 02 Mar, 2024 | Expired |
| US9827379 | Drive mechanisms suitable for use in drug delivery devices | 02 Mar, 2024 | Expired |
| US7476652 | Acidic insulin preparations having improved stability | 23 Jan, 2024 | Expired |
| US7713930 | Acidic insulin preparations having improved stability | 13 Dec, 2023 | Expired |
| US7476652 | Acidic insulin preparations having improved stability | 23 Jul, 2023 | Expired |
| US7713930 | Acidic insulin preparations having improved stability | 13 Jun, 2023 | Expired |
| US6960561 | Zinc-free and low-zinc insulin preparations having improved stability | 25 Jan, 2023 | Expired |
| US7148207 | Oral fludara of high-purity formulation with quick release of active ingredient | 20 Dec, 2022 | Expired |
| US7452860 | Zinc-free and low-zinc insulin preparations having improved stability | 22 Mar, 2022 | Expired |
| US7696162 | Zinc-free and low-zinc insulin preparations having improved stability | 22 Mar, 2022 | Expired |
| US5847170 | Taxoids, their preparation and pharmaceutical compositions containing them | 26 Sep, 2021 | Expired |
| US6514531 | Controlled-release dosage forms comprising zolpidem or a salt thereof | 01 Jun, 2020 | Expired |
| US6429210 | Polymorphic clopidogrel hydrogenesulphate form | 10 Dec, 2019 | Expired |
| US6504030 | Polymorphic form of clopidogrel hydrogen sulphate | 10 Dec, 2019 | Expired |
| US6514531 | Controlled-release dosage forms comprising zolpidem or a salt thereof | 01 Dec, 2019 | Expired |
| US6429210 | Polymorphic clopidogrel hydrogenesulphate form | 10 Jun, 2019 | Expired |
| US6504030 | Polymorphic form of clopidogrel hydrogen sulphate | 10 Jun, 2019 | Expired |
| US7547776 | Process for the production of fludarabine-phosphate lithium, sodium, potassium, calcium and magnesium salts and purification process for the production of fludarabine-phosphate and fludarabine-phosphate with a purity of at least 99.5% | 10 Dec, 2018 | Expired |
| US7323493 | Solid pharmaceutical composition containing benzofuran derivatives | 19 Jun, 2018 | Expired |
| US8318800 | Solid pharmaceutical compositions containing benzofuran derivatives | 19 Jun, 2018 | Expired |
| US6221633 | Insulin derivatives having a rapid onset of action | 18 Jun, 2018 | Expired |
| US5635485 | Erythromycin compounds | 01 Apr, 2018 | Expired |
| US5420319 | Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same | 09 Feb, 2017 | Expired |
| US5420319 | Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same | 09 Aug, 2016 | Expired |
| US5223510 | Alkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them | 26 Jul, 2016 | Expired |
| US5976573 | Aqueous-based pharmaceutical composition | 03 Jul, 2016 | Expired |
| US6143329 | Aqueous-based pharmaceutical composition | 03 Jul, 2016 | Expired |
| US7977045 | Aqueous-based pharmaceutical composition | 03 Jul, 2016 | Expired |
| US5847170 | Taxoids, their preparation and pharmaceutical compositions containing them | 26 Mar, 2016 | Expired |
| US6331635 | Taxoids, their preparation and pharmaceutical compositions containing them | 26 Mar, 2016 | Expired |
| US6372780 | Methods of treating cell lines expressing multidrug resistance P-glycoprotein | 26 Mar, 2016 | Expired |
| US6387946 | Methods for treating pathological conditions of abnormal cell proliferation | 26 Mar, 2016 | Expired |
| US5716988 | Pharmaceutically stable preparation of oxaliplatinum | 07 Feb, 2016 | Expired |
| US5994348 | Pharmaceutical compositions containing irbesartan | 07 Dec, 2015 | Expired |
| US6342247 | Pharmaceutical compositions containing irbesartan | 07 Dec, 2015 | Expired |
| USD459798 | Pill tablet | 24 Sep, 2015 | Expired |
| US5716988 | Pharmaceutically stable preparation of oxaliplatinum | 07 Aug, 2015 | Expired |
| US5994348 | Pharmaceutical compositions containing irbesartan | 07 Jun, 2015 | Expired |
| US6342247 | Pharmaceutical compositions containing irbesartan | 07 Jun, 2015 | Expired |
| US5656722 | A21 -, B30 - modified insulin derivatives having an altered action profile | 12 Feb, 2015 | Expired |
| US5679709 | Medicaments to combat autoimmune diseases | 21 Oct, 2014 | Expired |
| US5656722 | A21 -, B30 - modified insulin derivatives having an altered action profile | 12 Aug, 2014 | Expired |
| US5438072 | Taxoid-based compositions | 22 May, 2014 | Expired |
| US5438072 | Taxoid-based compositions | 22 Nov, 2013 | Expired |
| US5338874 | Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity | 07 Oct, 2013 | Expired |
| US5290961 | Platinum compound and process of preparing same | 12 Jul, 2013 | Expired |
| US5338874 | Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity | 07 Apr, 2013 | Expired |
| US5290961 | Platinum compound and process of preparing same | 12 Jan, 2013 | Expired |
| US5698582 | Compositions containing taxane derivatives | 03 Jan, 2013 | Expired |
| US5714512 | Compositions containing taxane derivatives | 03 Jan, 2013 | Expired |
| US5750561 | Compositions containing taxane derivatives | 03 Jan, 2013 | Expired |
| US5459163 | Medicament to combat autoimmune diseases | 17 Oct, 2012 | Expired |
| US5698582 | Compositions containing taxane derivatives | 03 Jul, 2012 | Expired |
| US5714512 | Compositions containing taxane derivatives | 03 Jul, 2012 | Expired |
| US5750561 | Compositions containing taxane derivatives | 03 Jul, 2012 | Expired |
Latest Legal Activities on Sanofi Aventis Us's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sanofi Aventis Us.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Jun, 2024 | US9533105 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Jun, 2024 | US9533105 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jan, 2024 | US9408979 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jan, 2024 | US9408979 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 03 Jan, 2024 | US10716777 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 Aug, 2023 | US10583110 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Jun, 2023 | US9233211 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Jun, 2023 | US9233211 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 01 Feb, 2023 | US9107900 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Oct, 2022 | US9011391 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Oct, 2022 | US9011391 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Sep, 2022 | US7918833 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Sep, 2022 | US7918833 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Sep, 2022 | US8992486 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Sep, 2022 | US8992486 (Litigated) |
Sanofi Aventis Us's Drug Patent Litigations
Sanofi Aventis Us's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 17, 2016, against patent number US5847170. The petitioner Mylan Laboratories Limited, challenged the validity of this patent, with Aventis Pharma S.A. as the respondent. Click below to track the latest information on how companies are challenging Sanofi Aventis Us's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8679069 | May, 2019 |
FWD Entered
(11 Aug, 2020)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
| US8603044 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US8992486 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US8992486 | October, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US9526844 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc |
| US9526844 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US9604008 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US8679069 | September, 2018 |
FWD Entered
(02 Apr, 2020)
| Sanofi-Aventis Deutshland GmbH | Mylan Pharmaceuticals Inc. |
| US9526844 | May, 2019 |
Terminated-Other
(20 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
| US9526844 | May, 2019 |
Terminated-Other
(19 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
| US8603044 | May, 2019 |
Terminated-Other
(15 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
| US8992486 | May, 2019 |
Terminated-Other
(15 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
| US9604008 | May, 2019 |
Terminated-Other
(15 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
| US5847170 | October, 2018 |
Terminated-Denied
(06 May, 2019)
| Aventis Pharma S.A. | Neptune Generics, LLC |
| US9526844 | September, 2018 |
Terminated-Denied
(03 Apr, 2019)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US8992486 | September, 2018 |
Terminated
(19 Dec, 2018)
| Sanofi-Aventis Deutschland GmbH et al. | Mylan Pharmaceuticals Inc et al. |
| US7476652 | June, 2017 |
FWD Entered
(12 Dec, 2018)
| Sanofi Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc., |
| US7713930 | June, 2017 |
FWD Entered
(12 Dec, 2018)
| Sanofi Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc., |
| US8927592 | March, 2016 |
Final Written Decision
(21 Sep, 2017)
| AVENTIS PHARMA S.A. et al. | Mylan Laboratories Limited et al. |
| US5847170 | February, 2016 |
Terminated-Denied
(23 Aug, 2016)
| Aventis Pharma S.A. | Mylan Laboratories Limited |
Sanofi Aventis Us Drug Patents' Oppositions Filed in EPO
Sanofi Aventis Us drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 14, 2013, by Stada Arzneimittel Ag. This opposition was filed on patent number EP04787385A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP10782039A | Dec, 2021 | Maiwald Patent- und Rechtsanwaltsgesellschaft mbH | Granted and Under Opposition |
| EP10782039A | Dec, 2021 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP10782039A | Dec, 2021 | Vossius & Partner Patentanwälte Rechtsanwälte mbB | Granted and Under Opposition |
| EP10782039A | Jun, 2021 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP10782039A | Mar, 2021 | Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH | Granted and Under Opposition |
| EP10782039A | Mar, 2021 | Fresenius Kabi Deutschland GmbH | Granted and Under Opposition |
| EP10782039A | Mar, 2021 | medac Gesellschaft für klinische Spezialpräparate mbH | Granted and Under Opposition |
| EP10782039A | Mar, 2021 | Zentiva k.s. | Granted and Under Opposition |
| EP10782039A | Mar, 2021 | EVER Valinject GmbH | Granted and Under Opposition |
| EP10782039A | Mar, 2021 | Glenmark Pharmaceuticals Europe Ltd | Granted and Under Opposition |
| EP10782039A | Mar, 2021 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP10782039A | Mar, 2021 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP10752585A | Jan, 2018 | Pentafarma Sociedade Técnico-Medicinal S.A. | Revoked |
| EP10752585A | Dec, 2017 | Wuesthoff & Wuesthoff Patentanwälte PartG mbB | Revoked |
| EP10752585A | Dec, 2017 | Cooke, Richard | Revoked |
| EP04787385A | Oct, 2013 | STADA Arzneimittel AG | Opposition rejected |
Sanofi Aventis Us's Family Patents
Sanofi Aventis Us Drug List
Given below is the complete list of Sanofi Aventis Us's drugs and the patents protecting them.
1. Ambien Cr
Ambien Cr is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6514531
(Pediatric)
| Controlled-release dosage forms comprising zolpidem or a salt thereof |
01 Jun, 2020
(4 years ago)
| Expired |
| US6514531 | Controlled-release dosage forms comprising zolpidem or a salt thereof |
01 Dec, 2019
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ambien Cr's drug page
2. Apidra
Apidra is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6960561 | Zinc-free and low-zinc insulin preparations having improved stability |
25 Jan, 2023
(1 year, 9 months ago)
| Expired |
| US7452860 | Zinc-free and low-zinc insulin preparations having improved stability |
22 Mar, 2022
(2 years ago)
| Expired |
| US7696162 | Zinc-free and low-zinc insulin preparations having improved stability |
22 Mar, 2022
(2 years ago)
| Expired |
| US6221633 | Insulin derivatives having a rapid onset of action |
18 Jun, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Apidra's drug page
3. Apidra Solostar
Apidra Solostar is protected by 23 patents, out of which 20 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9717852 | Cartridge holder and pen-type injector |
08 Apr, 2033
(8 years from now)
| Active |
| US7918833 | Pen-type injector |
23 Sep, 2027
(2 years from now)
| Active |
| US8679069 | Pen-type injector |
12 Apr, 2025
(4 months from now)
| Active |
| US8512297 | Pen-type injector |
15 Sep, 2024
(2 months ago)
| Expired |
| US9561331 | Drive mechanisms suitable for use in drug delivery devices |
28 Aug, 2024
(2 months ago)
| Expired |
| US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices |
19 Aug, 2024
(3 months ago)
| Expired |
| US9533105 | Drive mechanisms suitable for use in drug delivery devices |
17 Aug, 2024
(3 months ago)
| Expired |
| US9604009 | Drive mechanisms suitable for use in drug delivery devices |
16 Aug, 2024
(3 months ago)
| Expired |
| US8992486 | Pen-type injector |
05 Jun, 2024
(5 months ago)
| Expired |
| US9011391 | Pen-type injector |
26 Mar, 2024
(7 months ago)
| Expired |
| US8556864 | Drive mechanisms suitable for use in drug delivery devices |
03 Mar, 2024
(8 months ago)
| Expired |
| US8603044 | Pen-type injector |
02 Mar, 2024
(8 months ago)
| Expired |
| US9233211 | Relating to a pen-type injector |
02 Mar, 2024
(8 months ago)
| Expired |
| US9408979 | Pen-type injector |
02 Mar, 2024
(8 months ago)
| Expired |
| US9526844 | Pen-type injector |
02 Mar, 2024
(8 months ago)
| Expired |
| US9604008 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(8 months ago)
| Expired |
| US9610409 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(8 months ago)
| Expired |
| US9775954 | Pen-type injector |
02 Mar, 2024
(8 months ago)
| Expired |
| US9827379 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(8 months ago)
| Expired |
| US6960561 | Zinc-free and low-zinc insulin preparations having improved stability |
25 Jan, 2023
(1 year, 9 months ago)
| Expired |
| US7452860 | Zinc-free and low-zinc insulin preparations having improved stability |
22 Mar, 2022
(2 years ago)
| Expired |
| US7696162 | Zinc-free and low-zinc insulin preparations having improved stability |
22 Mar, 2022
(2 years ago)
| Expired |
| US6221633 | Insulin derivatives having a rapid onset of action |
18 Jun, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Apidra Solostar's drug page
4. Aubagio
Aubagio is protected by 8 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9186346
(Pediatric)
| Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
04 Aug, 2034
(9 years from now)
| Active |
| US9186346 | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
04 Feb, 2034
(9 years from now)
| Active |
| US8802735
(Pediatric)
| (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
14 Mar, 2031
(6 years from now)
| Active |
| US8802735 | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
14 Sep, 2030
(5 years from now)
| Active |
| US6794410
(Pediatric)
| Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
12 Mar, 2027
(2 years from now)
| Active |
| US6794410 | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
12 Sep, 2026
(1 year, 9 months from now)
| Active |
| US5679709 | Medicaments to combat autoimmune diseases |
21 Oct, 2014
(10 years ago)
| Expired |
| US5459163 | Medicament to combat autoimmune diseases |
17 Oct, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aubagio's drug page
5. Avalide
Avalide is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5994348
(Pediatric)
| Pharmaceutical compositions containing irbesartan |
07 Dec, 2015
(8 years ago)
| Expired |
| US5994348 | Pharmaceutical compositions containing irbesartan |
07 Jun, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Avalide's drug page
Explore Our Curated Drug Screens
6. Avapro
Avapro is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6342247
(Pediatric)
| Pharmaceutical compositions containing irbesartan |
07 Dec, 2015
(8 years ago)
| Expired |
| US6342247 | Pharmaceutical compositions containing irbesartan |
07 Jun, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Avapro's drug page
7. Eloxatin
Eloxatin is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5420319
(Pediatric)
| Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same |
09 Feb, 2017
(7 years ago)
| Expired |
| US5420319 | Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same |
09 Aug, 2016
(8 years ago)
| Expired |
| US5716988
(Pediatric)
| Pharmaceutically stable preparation of oxaliplatinum |
07 Feb, 2016
(8 years ago)
| Expired |
| US5716988 | Pharmaceutically stable preparation of oxaliplatinum |
07 Aug, 2015
(9 years ago)
| Expired |
| US5338874
(Pediatric)
| Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity |
07 Oct, 2013
(11 years ago)
| Expired |
| US5290961
(Pediatric)
| Platinum compound and process of preparing same |
12 Jul, 2013
(11 years ago)
| Expired |
| US5338874 | Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity |
07 Apr, 2013
(11 years ago)
| Expired |
| US5290961 | Platinum compound and process of preparing same |
12 Jan, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Eloxatin's drug page
8. Jevtana Kit
Jevtana Kit is protected by 13 patents, out of which 7 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8927592
(Pediatric)
| Antitumoral use of cabazitaxel |
27 Apr, 2031
(6 years from now)
| Active |
| US10583110 | Antitumoral use of cabazitaxel |
27 Oct, 2030
(5 years from now)
| Active |
| US10716777 | Antitumoral use of cabazitaxel |
27 Oct, 2030
(5 years from now)
| Active |
| US8927592 | Antitumoral use of cabazitaxel |
27 Oct, 2030
(5 years from now)
| Active |
| US7241907
(Pediatric)
| Acetone solvate of dimethoxy docetaxel and its process of preparation |
10 Jun, 2026
(1 year, 6 months from now)
| Active |
| US7241907 | Acetone solvate of dimethoxy docetaxel and its process of preparation |
10 Dec, 2025
(1 year, 18 days from now)
| Active |
| US5847170
(Pediatric)
| Taxoids, their preparation and pharmaceutical compositions containing them |
26 Sep, 2021
(3 years ago)
| Expired |
| US5847170 | Taxoids, their preparation and pharmaceutical compositions containing them |
26 Mar, 2016
(8 years ago)
| Expired |
| US6331635 | Taxoids, their preparation and pharmaceutical compositions containing them |
26 Mar, 2016
(8 years ago)
| Expired |
| US6372780 | Methods of treating cell lines expressing multidrug resistance P-glycoprotein |
26 Mar, 2016
(8 years ago)
| Expired |
| US6387946 | Methods for treating pathological conditions of abnormal cell proliferation |
26 Mar, 2016
(8 years ago)
| Expired |
| US5438072 | Taxoid-based compositions |
22 Nov, 2013
(11 years ago)
| Expired |
| US5698582 | Compositions containing taxane derivatives |
03 Jul, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jevtana Kit's drug page
9. Ketek
Ketek is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5635485 | Erythromycin compounds |
01 Apr, 2018
(6 years ago)
| Expired |
| USD459798 | Pill tablet |
24 Sep, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ketek's drug page
10. Lantus
Lantus is protected by 8 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7918833
(Pediatric)
| Pen-type injector |
23 Mar, 2028
(3 years from now)
| Active |
| US7918833 | Pen-type injector |
23 Sep, 2027
(2 years from now)
| Active |
| US7476652
(Pediatric)
| Acidic insulin preparations having improved stability |
23 Jan, 2024
(9 months ago)
| Expired |
| US7713930
(Pediatric)
| Acidic insulin preparations having improved stability |
13 Dec, 2023
(11 months ago)
| Expired |
| US7476652 | Acidic insulin preparations having improved stability |
23 Jul, 2023
(1 year, 4 months ago)
| Expired |
| US7713930 | Acidic insulin preparations having improved stability |
13 Jun, 2023
(1 year, 5 months ago)
| Expired |
| US5656722
(Pediatric)
| A21 -, B30 - modified insulin derivatives having an altered action profile |
12 Feb, 2015
(9 years ago)
| Expired |
| US5656722 | A21 -, B30 - modified insulin derivatives having an altered action profile |
12 Aug, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lantus's drug page
11. Lantus Solostar
Lantus Solostar is protected by 18 patents, out of which 16 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9717852 | Cartridge holder and pen-type injector |
08 Apr, 2033
(8 years from now)
| Active |
| US8679069 | Pen-type injector |
12 Apr, 2025
(4 months from now)
| Active |
| US8512297 | Pen-type injector |
15 Sep, 2024
(2 months ago)
| Expired |
| US9561331 | Drive mechanisms suitable for use in drug delivery devices |
28 Aug, 2024
(2 months ago)
| Expired |
| US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices |
19 Aug, 2024
(3 months ago)
| Expired |
| US9533105 | Drive mechanisms suitable for use in drug delivery devices |
17 Aug, 2024
(3 months ago)
| Expired |
| US9604009 | Drive mechanisms suitable for use in drug delivery devices |
16 Aug, 2024
(3 months ago)
| Expired |
| US8992486 | Pen-type injector |
05 Jun, 2024
(5 months ago)
| Expired |
| US9011391 | Pen-type injector |
26 Mar, 2024
(7 months ago)
| Expired |
| US8556864 | Drive mechanisms suitable for use in drug delivery devices |
03 Mar, 2024
(8 months ago)
| Expired |
| US8603044 | Pen-type injector |
02 Mar, 2024
(8 months ago)
| Expired |
| US9233211 | Relating to a pen-type injector |
02 Mar, 2024
(8 months ago)
| Expired |
| US9408979 | Pen-type injector |
02 Mar, 2024
(8 months ago)
| Expired |
| US9526844 | Pen-type injector |
02 Mar, 2024
(8 months ago)
| Expired |
| US9604008 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(8 months ago)
| Expired |
| US9610409 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(8 months ago)
| Expired |
| US9775954 | Pen-type injector |
02 Mar, 2024
(8 months ago)
| Expired |
| US9827379 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lantus Solostar's drug page
12. Multaq
Multaq is protected by 6 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8602215 | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
30 Jun, 2031
(6 years from now)
| Active |
| US8410167 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
16 Apr, 2029
(4 years from now)
| Active |
| US9107900 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality |
16 Apr, 2029
(4 years from now)
| Active |
| US7323493 | Solid pharmaceutical composition containing benzofuran derivatives |
19 Jun, 2018
(6 years ago)
| Expired |
| US8318800 | Solid pharmaceutical compositions containing benzofuran derivatives |
19 Jun, 2018
(6 years ago)
| Expired |
| US5223510 | Alkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them |
26 Jul, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Multaq's drug page
13. Nasacort Aq
Nasacort Aq is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5976573 | Aqueous-based pharmaceutical composition |
03 Jul, 2016
(8 years ago)
| Expired |
| US6143329 | Aqueous-based pharmaceutical composition |
03 Jul, 2016
(8 years ago)
| Expired |
| US7977045 | Aqueous-based pharmaceutical composition |
03 Jul, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nasacort Aq's drug page
14. Oforta
Oforta is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7148207 | Oral fludara of high-purity formulation with quick release of active ingredient |
20 Dec, 2022
(1 year, 11 months ago)
| Expired |
| US7547776 | Process for the production of fludarabine-phosphate lithium, sodium, potassium, calcium and magnesium salts and purification process for the production of fludarabine-phosphate and fludarabine-phosphate with a purity of at least 99.5% |
10 Dec, 2018
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oforta's drug page
15. Plavix
Plavix is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6429210
(Pediatric)
| Polymorphic clopidogrel hydrogenesulphate form |
10 Dec, 2019
(4 years ago)
| Expired |
| US6504030
(Pediatric)
| Polymorphic form of clopidogrel hydrogen sulphate |
10 Dec, 2019
(4 years ago)
| Expired |
| US6429210 | Polymorphic clopidogrel hydrogenesulphate form |
10 Jun, 2019
(5 years ago)
| Expired |
| US6504030 | Polymorphic form of clopidogrel hydrogen sulphate |
10 Jun, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Plavix's drug page
16. Taxotere
Taxotere is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5438072
(Pediatric)
| Taxoid-based compositions |
22 May, 2014
(10 years ago)
| Expired |
| US5438072 | Taxoid-based compositions |
22 Nov, 2013
(11 years ago)
| Expired |
| US5698582
(Pediatric)
| Compositions containing taxane derivatives |
03 Jan, 2013
(11 years ago)
| Expired |
| US5714512
(Pediatric)
| Compositions containing taxane derivatives |
03 Jan, 2013
(11 years ago)
| Expired |
| US5750561
(Pediatric)
| Compositions containing taxane derivatives |
03 Jan, 2013
(11 years ago)
| Expired |
| US5698582 | Compositions containing taxane derivatives |
03 Jul, 2012
(12 years ago)
| Expired |
| US5714512 | Compositions containing taxane derivatives |
03 Jul, 2012
(12 years ago)
| Expired |
| US5750561 | Compositions containing taxane derivatives |
03 Jul, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Taxotere's drug page